Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

‘They hate it’: House Minority Whip describes Americans' rejection of Trump's tax bill Widow of officer who died by suicide ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...

Sixty-three percent of patients starting on Novo Nordisk's Wegovy or Eli Lilly's Zepbound during the first quarter of 2024 ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new ...